The Utility of Acute-Phase Proteins in the Assessment of Treatment Response in Dogs With Bacterial Pneumonia

Viitanen, S. J.; Lappalainen, A. K.; Christensen, M. B.; Sankari, S.; Rajamäki, M. M.

Published in:
Journal of Veterinary Internal Medicine

DOI:
10.1111/jvim.14631

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY-NG

Citation for published version (APA):
Viitanen, S. J., Lappalainen, A. K., Christensen, M. B., Sankari, S., & Rajamäki, M. M. (2017). The Utility of Acute-Phase Proteins in the Assessment of Treatment Response in Dogs With Bacterial Pneumonia. Journal of Veterinary Internal Medicine, 31(1), 124-133. https://doi.org/10.1111/jvim.14631
The Utility of Acute-Phase Proteins in the Assessment of Treatment Response in Dogs With Bacterial Pneumonia

S.J. Viitanen, A.K. Lappalainen, M.B. Christensen, S. Sankari, and M.M. Rajamäki

Background: Acute-phase proteins (APPs) are sensitive markers of inflammation, and serum C-reactive protein (CRP) recently has been shown to be a useful diagnostic marker in dogs with bacterial pneumonia (BP). In humans with community-acquired pneumonia, APPs also have great utility as follow-up markers aiding in the assessment of treatment response.

Objectives: The aim of our study was to investigate the applicability of APPs as markers of treatment response in dogs with BP.

Animals: Nineteen dogs diagnosed with BP and 64 healthy dogs.

Methods: The study was conducted as a prospective longitudinal observational study. Serum CRP, serum amyloid A (SAA), and haptoglobin concentrations were followed during a natural course of BP. Normalization of serum CRP was used to guide the duration of antibiotic treatment (treatment was stopped 5–7 days after CRP normalized) in 8 of 17 dogs surviving to discharge; 9 of 17 dogs were treated according to conventional recommendations.

Results: All measured APPs initially were significantly increased, but the magnitude of increase was not correlated to disease severity. C-reactive protein and SAA concentrations decreased rapidly after initiation of antimicrobial treatment. When normalization of serum CRP was used to guide the duration of antibiotic treatment, treatment duration was significantly decreased (P = 0.015) without increasing the number of relapses.

Conclusions and Clinical Importance: Serum CRP and SAA reflected the recovery process well and therefore may be used as markers of treatment response. According to the results, the normalization of serum CRP may be used to guide the duration of antibiotic treatment in dogs with BP.

Key words: Canine; C-reactive protein; Haptoglobin; Serum amyloid A.

Bacterial pneumonia (BP) is an acquired inflammation of the lower airways and lung parenchyma secondary to bacterial infection. The clinical characteristics and microbiological findings in dogs with BP have been well described. However, information concerning the normalization of clinical and radiographic findings during the recovery process and guidelines on assessing the optimal duration of antibiotic treatment in BP still are limited.

Acute-phase proteins (APPs) are a group of blood proteins, mainly produced by the liver, which are part of the innate host defense system. The APPs are involved in the protection against infection as well as in the regulation of the immune response and inflammation, especially in the early phases of injury. The major positive APPs in dogs, C-reactive protein (CRP) and serum amyloid A (SAA), have low serum concentrations in healthy dogs. Serum concentrations of CRP and SAA increase markedly within the first hours after inflammatory stimuli and normalize quickly during the recovery period.

The APPs have certain advantages in disease monitoring compared to the CBC. The numbers of blood leukocytes are largely affected by extravasation into the pulmonary parenchyma during acute BP, whereas APPs increase consistently with increasing...
inflammatory stimuli. Minor and moderate positive APPs, such as haptoglobin (Hp), show a more gradual increase and decrease during the acute-phase response (APR). The production of other plasma proteins, so-called negative APPs (such as albumin and transferrin), decreases during the APR.

Being nonspecific biomarkers of inflammation, increased serum concentrations of CRP, SAA, and Hp have been observed in dogs with a variety of infectious, immune-mediated, and neoplastic diseases. Despite the nonspecific nature of APPs, serum CRP can be useful in discriminating disease processes such as BP from other pulmonary diseases.

The APPs have been shown to decrease after initiation of successful treatment. Additionally, the increase in serum CRP during long-term follow-up in dogs with leishmaniasis and immune-mediated polyarthritis predicts the relapse of clinical disease.

The utilization of CRP and SAA as possible prognostic biomarkers also has been studied in dogs, and most studies concluded that serum CRP or SAA concentrations at presentation could predict poor outcome. However, persistent increases in serum CRP after 48–72 hours of treatment were correlated with poor outcome. Serum CRP has been widely studied in humans with community-acquired pneumonia (CAP), and its use as a diagnostic and follow-up biomarker is recommended by current treatment guidelines.

Bacterial pneumonia currently is treated with markedly longer antimicrobial courses than is CAP, and effective means to estimate optimal treatment duration are lacking. Biomarker-guided antimicrobial treatment has been studied in humans with CAP by procalcitonin (PCT), a novel inflammatory biomarker, which indicated that PCT-guided antibiotic use decreased the duration of antimicrobial treatment without increasing the incidence of complications. Similar studies assessing CRP-guided antimicrobial use in humans with CAP are lacking, but serum CRP has been shown to be useful in decreasing the duration of antimicrobial treatment in humans with neonatal septicemia without increasing the incidence of complications.

The aim of our study was to describe the changes in clinical variables, thoracic radiographs, and APPs during a natural course of BP in dogs as well as comparing these variables between dogs with less severe BP requiring <2 days of hospitalization (lsBP) and more severe BP requiring >2 days of hospitalization (msBP). Additionally, the purpose of our study was to provide information concerning the application of APPs in the assessment of treatment response and to investigate whether serum CRP measurements can aid in the estimation of antimicrobial treatment duration in dogs with BP.

Materials and Methods

Study Design

This study was conducted as a prospective longitudinal observational study.

Study Population

Privately owned dogs diagnosed with BP between March 2011 and December 2012 at the Veterinary Teaching Hospital of the University of Helsinki were eligible for inclusion in the study. Dogs with known or suspected concurrent infectious, inflammatory or neoplastic diseases capable of increasing APP concentrations were excluded from the study. Dogs with known excess endogenous glucocorticoids or glucocorticoid medication <4 weeks before BP were excluded from the Hp measurements. Pregnant or lactating bitches and puppies <3 months of age also were excluded. Privately owned blood donor dogs were recruited as healthy controls for the APP measurements. These dogs had no signs of illness and had a normal physical examination findings as well as normal hematology and biochemistry findings.

Diagnostic Testing, Sample Collection, and Follow-Up

A full clinical examination was performed, and thoracic radiographs as well as blood, fecal, and respiratory samples were obtained at presentation as previously described. Thoracic radiographs were assessed by the same radiologist (AKL), who was blinded to the patient data. Bacterial pneumonia was diagnosed when typical acute signs (at least 3 of the following: fever, lethargy, dyspnea, tachypnea, cough) were observed and thoracic radiograph findings were compatible with BP (ie, an alveolar pattern or a moderate or severe bronchointerstitial or interstitial pattern). A bacterial origin was demonstrated by respiratory cytology or bacterial culture as previously described. A postmortem examination was performed on dogs that died or were euthanized during hospitalization, to confirm the diagnosis of BP.

After initial examination, dogs were examined daily during hospitalization (clinical examination and individually chosen methods including blood tests, thoracic imaging, or both) and at follow-up visits at 7- to 10-day intervals after discharge. The last follow-up visit was scheduled 2 weeks after antimicrobial treatment had concluded. A clinical examination was performed during the follow-up visits, and blood samples for hematology, APP measurements, and arterial blood gas analysis were obtained and thoracic radiographs were repeated. Owners were contacted 4–8 weeks after the last follow-up visit to obtain information on possible relapses.

Initially, antimicrobial treatment was chosen empirically to cover the most common causative organisms in BP. Later, when bacterial culture and antimicrobial susceptibility results were available, the treatment regimen was re-evaluated, and if necessary, changes were made according to the culture results. During hospitalization, antimicrobials were administrated IV, and PO treatment was continued after discharge. Dogs were discharged when they did not require oxygen supplementation and were capable of maintaining normal hydration and nutrition PO. At the beginning of the trial, the duration of antimicrobial treatment followed conventional recommendations, and dogs were treated for 3–6 weeks or 1–2 weeks beyond the resolution of alveolar density on the thoracic radiographs. Antimicrobial treatment of dogs entering our study during 2012 was discontinued 5–7 days after serum CRP returned to normal (<25 mg/L). Antibiotic treatment was discontinued by the CRP-guided approach only when owners consented.

Sample Handling and Analysis

Hematology, serum biochemistry, arterial blood gas analysis, blood cultures, and fecal analysis along with cytological and microbiological analysis of respiratory samples were performed as previously described. Coagulation parameters prothrombin time (PT) and activated partial thromboplastin time (aPTT) were evaluated with commercial test kits for dogs. Serum samples
obtained for APP analysis either were immediately analyzed or stored at −80°C until analyzed. CRP was analyzed by magnetic permeability-based immunoassay validated for dogs. C-reactive protein values below the detection limit for the CRP assay (<10 mg/L) were set at 5 mg/L. Results above the upper detection limit for the assay (>210 mg/L) were set at 211 mg/L. A CRP ratio (CRP concentrations at 24, 48, and 72 hour divided by the initial concentration), describing the decrease in CRP during early recovery, was calculated after initiation of treatment in dogs with samples available for the time point in question. Samples for SAA analysis were sent on dry ice to an external laboratory and measured by an automated latex agglutination test validated for dogs. Haptoglobin was measured by a commercial colorimetric method validated for dogs.

### Statistical Analyses

Normality testing was performed by Shapiro–Wilk’s test of normality and normal Q–Q plots. The differences between dogs with bSBP and mSBP as well as between dogs with *Escherichia coli*-induced BP and BP caused by other organisms were evaluated by the independent samples Student’s t-test (normally distributed variables) and Mann–Whitney U-test (non-normally distributed variables). The Mann–Whitney U-test also was used to evaluate whether there were differences in bronchoalveolar lavage fluid (BALF) and transtracheal wash (TTW) fluid differential cell counts and whether the duration of antimicrobial treatment differed in dogs with CRP-guided and conventional treatment. Initial serum CRP, SAA, Hp, and albumin concentrations were compared among groups of healthy dogs as well as dogs with concurrent disease processes possibly predisposing to the development of BP were identified in 6 of 19 dogs to the antibiotics used. One dog was euthanized as a consequence of refractory BP caused by a multiresistant *E. coli*. None of the owners refused hospitalization or selected euthanasia for financial reasons.

### Results

#### Dogs

Nineteen dogs diagnosed with BP were included, and 64 privately owned healthy blood donor dogs were chosen as controls for the APP measurements. Age, body weight, and sex distribution of dogs participating in our study are presented in Table 1. The dogs represented various breeds without overrepresentation of any single breed.

All dogs were presented as acute emergency cases of varying severity. Fifteen of 19 dogs required hospitalization. One dog died as a consequence of severe BP despite the fact that the bacteria isolated were susceptible to the antibiotics used. One dog was euthanized as a consequence of refractory BP caused by a multiresistant *E. coli*. None of the owners refused hospitalization or selected euthanasia for financial reasons.

Concurrent disease processes possibly predisposing to the development of BP were identified in 6 of 19 dogs (parainfluenza or respiratory corona virus infection [5/6], advanced chronic bronchitis [1/6]).

### Table 1. Microbiological findings of respiratory samples (bronchoalveolar lavage fluid n = 11, transtracheal wash fluid n = 5, transthoracic fine-needle aspiration n = 2, and fresh sputum sample n = 1) and blood cultures in dogs with bacterial pneumonia (n = 19).

| Antimicrobial treatment before sampling | Dogs with Significant Bacterial Growth in Primary Culture (n = 12) | Dogs with Bacterial Growth After Enrichment (n = 5) | Dogs with No Bacterial Growth (n = 2) |
|----------------------------------------|---------------------------------------------------------------|-----------------------------------------------|--------------------------------------|
| Blood culture results                  | *Escherichia coli* 3/12                                      | *Actinomyces* sp. 2/5                         | *Streptococcus* sp. 1/5               |
|                                        | *Pasteurella* sp. 2/12                                      | *Streptococcus* sp. 1/5                       | *Haemophilus* sp. 1/5                 |
|                                        | *Streptococcus* sp. 2/12                                    | *Streptococcus* sp. 1/5                       |                                      |
|                                        | *Haemophilus* sp. 1/12                                      | *Streptococcus* sp. 1/5                       |                                      |
|                                        | *Mycoplasma* sp. 1/12                                       | *Haemophilus* sp. 1/5                         |                                      |
|                                        | *Actinomyces* sp. 1/12                                      |                                               |                                      |
|                                        | *Nocardiopsis* sp. 1/12                                     |                                               |                                      |
|                                        | *E. coli* and *Arcanobacter* sp. 1/12                       |                                               |                                      |
| Intracellular bacteria in cytology or Gram stain | 7/12                                                        | 1/5                                           | 0/2                                  |
| Blood culture performed                | 5/12                                                         | 4/5                                           | 1/2                                  |
| Positive blood culture                 | 2/5                                                         | 1/4                                           | 0/1                                  |
| Blood culture results                  | *E. coli* 2/2                                               | *Staphylococcus* sp. 1/1                      |                                      |
| Blood culture consistent with respiratory culture | 2/2                                                         |                                               | 0/1                                  |
Clinical Findings

Clinical data as well as duration of clinical signs and hospitalization are presented in Table 1. Fecal analyses were available for 15 of 19 dogs, and each sample was negative for lungworms and intestinal parasites. Prothrombin time and aPTT were measured in 8 of 19 dogs on 15 different occasions either at presentation or during hospitalization. Prothrombin time was normal in all measurements. Mildly prolonged aPTT was noted in 3 of 8 dogs. In all 3 dogs, E. coli was detected in respiratory samples. One of these dogs was hospitalized for 5 days; 2 did not survive to hospital discharge.

Acute-Phase Proteins Measurements

Serum CRP, SAA, and Hp concentrations are presented in Figure 1A–C. In 3 dogs, initial serum CRP concentrations exceeded the upper detection limit for the assay (>210 mg/L) were set at 211 mg/L. Three dogs had received exogenous glucocorticoids (a single PO dose of prednisolone or hydrocortisone [2/3] and daily inhaled fluticasone [1/3]) before inclusion and 1 dog was diagnosed with Cushing’s disease after the study period. Serum CRP and SAA (r = 0.60, P = .015), CRP and Hp (r = 0.61, P = .010) as well as SAA and Hp (r = 0.85, P < .001) at presentation were significantly positively correlated. Serum amyloid A concentration was significantly negatively correlated with serum albumin concentration (r = −0.53, P = .035), but CRP (r = −0.22, P = .40) and Hp (r = −0.15, P = .58) were not. Serum APPs at presentation were not significantly correlated with variables of disease severity, such as duration of hospitalization (CRP: r = 0.36, P = .24; SAA: r = 0.462, P = .072; Hp: r = 0.305, P = .235), arterial PaO2 (CRP: r = 0.353, P = .138; SAA: r = −0.450, P = .080; Hp: r = −0.48, P = .052), or A-a O2 (CRP: r = 0.35, P = .14; SAA: r = 0.42, P = .11; Hp: r = 0.42, P = .090).

Changes in serum CRP, SAA, Hp, and in arterial PaO2 during the follow-up period are presented in Figure 2A–D.

The CRP ratio was calculated for hospitalized patients at 24 hours (median, 1.0; interquartile range [IQR], 0.6–2.2; n = 11), 48 hours (median, 0.95; IQR, 0.8–1.1; n = 8), and 72 hours (median, 1.0; IQR, 0.8–1.2; n = 5). C-reactive protein concentration continued to increase in the first 24 hours in 5 of 11 dogs. The CRP ratios after 24 hours (r = 0.35, P = .30), 48 hours (r = 0.46, P = .25), and 72 hours (r = −0.15, P = .81) were not correlated with the duration of hospitalization.

Radiographic Findings

An alveolar lung pattern was detected in 15 of 19 dogs, involving a single lobe in 5 of 15 dogs and multiple lobes in 9 of 15 dogs. A patchy alveolar pattern involving several lobes was found in 1 dog. The cranial (12/15) and middle (7/15) lobes most often were affected. A moderate-to-severe interstitial or bronchointerstitial lung pattern was identified in 4 of 19 dogs at presentation. An alveolar pattern in multiple lobes at presentation was detected in 4 of 10 dogs with lsBP and in 6 of 9 dogs with msBP.

The alveolar pattern found in 13 of 17 dogs was resolved in a median of 10 days (IQR, 8–15 days), and 9 of 13 dogs had cleared alveolar infiltrates by day 10. At a follow-up visit 2 weeks after discontinuation of antibiotics, 15 of 17 dogs still had a mild-to-moderate bronchial, bronchointerstitial, or interstitial patterns on thoracic radiographs.

Respiratory Samples

Bronchoalveolar lavage fluid was retrieved in 11 of 19, and TTW was performed in 5 of 19. When BAL or TTW were not available (mainly due to the small size of the patient or the severity of BP), a transthoracic aspirate (TTA) was collected in 2 of 19 and a fresh sputum sample in 1 of 19 dogs. Microbiological analysis was performed in all dogs and the results are presented in Table 1. A cytological analysis was performed in 18 of 19 dogs (cytology was not performed on 1 TTW sample). Results from the cytology analyses are presented in Table 2. Because BALF and TTW fluid cytology did not differ significantly in other cell percentages apart from the percentage of epithelial cells (median in BALF, 0.0; IQR, 0.0–0.0 versus median in TTW fluid, 7.1; IQR, 0.2–16.1; P = .026), combined results are presented for the 2 sampling techniques. Cytology in TTA (n = 2) and fresh sputum (n = 1) samples consisted of markedly increased numbers of neutrophils and intraacellular bacteria, and an abundant bacterial growth was detected in these samples. The diagnosis of BP was additionally confirmed by postmortem examination in 1 dog with sputum sampling and in 1 dog with TTA sampling.

Dogs with E. coli as a causative agent required significantly (P = .049) longer hospitalization (median, 4.5 days; range, 3.5–5.5) compared to dogs with other causative bacteria (median, 1.0 days; range, 0.5–14.0) and 2 of 4 dogs with E. coli-induced BP died or were euthanized because of disease severity.

Duration of Antimicrobial Treatment

Of the 17 dogs surviving to discharge, 9 received antibiotics according to conventional recommendations (median duration of treatment, 35 days; IQR, 29–48 days) and CRP was not used for determining the duration of the treatment. Less severe BP and msBP were observed in 6 of 9 and 3 of 9 of these dogs, respectively. Antimicrobial treatment was discontinued 5–7 days after CRP normalization in 8 of 17 dogs (median duration of treatment, 21 days; IQR, 19–29 days). Less severe BP and msBP were observed in 4 of 8 and 4 of 8 of these dogs, respectively. Treatment guided by CRP (median, 21 days) was significantly shorter (P = .015) than conventional treatment (median, 35 days). Sixteen of 17 dogs did not have clinical signs or findings suggestive of BP relapse at follow-up visits 2 weeks after antibiotic discontinuation or during follow-up phone
calls 4–8 weeks after the follow-up visit. One dog treated conventionally had a relapse of BP after antibiotic discontinuation, and Cushing’s disease was later found as a predisposing factor. Bacteria susceptible to the initially chosen antimicrobials were detected in 15 of 17 dogs. In 2 dogs, bacterial growth was not detected and therefore antimicrobial susceptibility could not be addressed. Of these 2 dogs, 1 was treated according to conventional recommendations and 1 was treated by CRP guidance.

**Discussion**

All measured positive APPs were significantly increased in dogs with BP at presentation compared to healthy controls. This finding is in agreement with previous reports describing CRP and SAA in dogs with BP. Haptoglobin concentrations have not been reported previously, but because significant increases in serum Hp have been reported 24 hours after an inflammatory stimulus, increased concentrations also were expected in BP. However, it must be emphasized that APPs are highly nonspecific inflammatory markers and, in addition to BP, increased concentrations may be encountered in a variety of disease processes.

As expected, all positive APPs (CRP, SAA, Hp) correlated positively with each other. However, a negative correlation with albumin did not occur in all comparisons. This is most likely due to the long half-life of albumin, resulting in a late response not noticeable in acute BP.

Serum APP concentrations at presentation did not differ significantly in dogs with lsBP and msBP. Additionally, serum CRP, SAA, or Hp at presentation did not correlate significantly with markers of disease severity, such as arterial PaO₂ and the duration of hospitalization. Initial serum CRP, SAA, or Hp concentrations in dogs with BP therefore may not be useful indicators of disease severity. A similar observation has been made in studies describing CRP in human patients with CAP.

C-reactive protein and SAA rapidly decreased after initiation of treatment (Fig 2A,B). These findings indicate that CRP and SAA are useful markers of treatment response. Haptoglobin showed a more gradual increase and decrease and therefore did not reflect clinical recovery as well as CRP and SAA. Because there is a wider range of concentrations and the magnitude of change is more pronounced in SAA compared to CRP, SAA might be a better diagnostic and follow-up marker than CRP in dogs with BP, as already suggested by a recent study comparing CRP and SAA as diagnostic markers of systemic inflammation.
C-reactive protein continued to increase within the first 24 hours in 5 dogs. This is not unexpected because dogs with BP were presented acutely and CRP is known to reach peak concentrations approximately 24 hours after the onset of an inflammatory stimulus. Consequently, it is not meaningful to interpret the possible CRP decrease as early as 24 hours after initiation of treatment. However, a decrease in serum CRP is expected 48–72 hours after initiation of successful treatment, and a failure to show a decrease has been associated with a poor prognosis in dogs with systemic inflammatory conditions. Consecutive measurements of CRP have been to be found useful in humans with CAP, and the magnitude of CRP decrease at days 3 and 4 has been shown to have prognostic value. A connection also has been shown between the pattern of serum CRP concentrations and outcome in humans. Patients with persistently high CRP (so-called nonresponse) or an increase in serum CRP after an initial decrease (so-called biphasic response) during the first days of hospitalization had a poor prognosis. In our study, the CRP ratio, describing the magnitude of

Fig 2. (A–D) Geometric mean curves for serum C-reactive protein (CRP) and serum amyloid A (SAA) concentrations as well as mean curves for serum haptoglobin (Hp) concentrations and partial pressure of arterial oxygen (PaO2) values over time during a natural course of bacterial pneumonia (BP). A solid line represents dogs with less severe disease (requiring <2 days of hospitalization; CRP, SAA and PaO2 n = 10, Hp n = 9), and a dashed line represents dogs with more severe BP (requiring >2 days of hospitalization; CRP and PaO2 n = 9, SAA n = 7, Hp n = 6, including 2 mortalities). Individual measurements are marked with a circle (o) for dogs with a less severe disease and with a plus sign (+) for dogs with a more severe disease.
Table 2. Comparison of demographic, clinical, and respiratory cytology findings at presentation in dogs with less severe bacterial pneumonia (BP) (requiring <2 days of hospitalization, n = 10) and more severe BP (requiring >2 days of hospitalization, n = 9, including 2 mortalities).  

|                              | Dogs with <2 Days of Hospitalization | Dogs with >2 Days Hospitalization | P-Value |
|------------------------------|-------------------------------------|----------------------------------|---------|
|                              | Mean ± SD or Median (IQR)           | Mean ± SD or Median (IQR)        |         |
| Duration of hospitalization (days) | 1.0 (0.5–1.1)                      | 5.5 (3.3–5.8)                    | .211    |
| Age (years)                  | 1.5 (0.8–5.6)                      | 5.8 (2.6–7.6)                    | .211    |
| Sex                          | Male 6/10                           | Male 5/9                         |         |
|                              | Female 4/10                          | Female 4/9                       |         |
| Duration of clinical signs (days) | 3.0 (1.0–7.0)                      | 1.5 (1.0–3.5)                    | .315    |
| Body weight (kg)             | 36.5 ± 17.5                         | 33.6 ± 24.6                      | .764    |
| Body temperature (°C)        | 39.3 ± 0.9                          | 39.6 ± 0.9                       | .419    |
| Respiratory rate (breaths/min) | 43 ± 22                             | 61 ± 17                          | .064    |
| Blood hematology (n = 19)    |                                     |                                  |         |
| Leukocyte count (10^9/L)     | 20.2 ± 16.3                         | 12.1 ± 6.5                       | .183    |
| Segment neutrophil count (10^9/L) | 15.9 ± 14.2                       | 9.3 ± 5.5                        | .234    |
| Band neutrophil count (10^9/L) | 0.1 (0.0–0.7)                     | 1.4 (0.3–2.8)                    | .035    |
| Lymphocyte count (10^9/L)    | 2.2 ± 1.6                           | 0.5 ± 0.3                        | .009    |
| Eosinophil count (10^9/L)    | 0.4 ± 0.4                           | 0.1 ± 0.2                        | .078    |
| Monocyte count (10^9/L)      | 0.7 (0.4–2.3)                       | 0.4 (0.2–1.4)                    | .278    |
| Basophil count (10^9/L)      | 0.0 (0.0–0.0)                       | 0.0 (0.0–0.0)                    | .720    |
| Arterial blood gas analysis (n = 19) |                                 |                                  |         |
| Arterial PaO2 (mmHg)         | 84.6 ± 6.8                          | 69.0 ± 9.8                       | .001    |
| Arterial Paco2 (mmHg)        | 30.8 (27.0–31.1)                    | 28.8 (28.4–32.2)                 | .842    |
| Alveolar–arterial O2 gradient| 30.8 ± 10.8                         | 46.5 ± 9.2                       | .003    |
| pH                           | 7.41 ± 0.02                         | 7.41 ± 0.6                       | .893    |
| HCO3 (mmol/L)                | 18.2 ± 1.7                          | 18.7 ± 3.4                       | .669    |
| Base excess (mEq/L)          | −4.6 ± 1.3                          | −4.3 ± 3.9                       | .833    |
| Respiratory sample cytology (n = 15) |                                 |                                  |         |
| Neutrophils (%)              | 14.7 (5.3–76.2)                     | 96.4 (46.8–97.8)                 | .019    |
| Eosinophils (%)              | 3.7 (0.6–13.2)                      | 0.0 (0.0–0.4)                    | .008    |
| Mast cells (%)               | 0.0 (0.0–2.7)                       | 0.0 (0.0–0.0)                    | .254    |
| Lymphocytes (%)              | 14.6 ± 11.2                         | 2.3 ± 3.1                        | .008    |
| Macrophages (%)              | 42.9 ± 22.9                         | 17.2 ± 27.6                      | .077    |
| Epithelial cells (%)         | 0.0 (0.0–0.2)                       | 0.0 (0.0–8.5)                    | 1.000    |

SD, standard deviation; IQR, interquartile range.

decrease after 48 or 72 hours, did not correlate with the duration of hospitalization. This finding could be a consequence of the small number of samples available for CRP measurement at 72 hours: Only 5 dogs with msBP were still alive and hospitalized 72 hours after presentation. Another limitation concerns the method used for CRP measurements. The upper detection limit for the assay used was 210 mg/L, and measurements exceeding this concentration were set at 211 mg/L. Doing so underestimated the increase in serum CRP, because it has been shown that serum CRP can increase markedly above 211 mg/L in dogs with aspiration pneumonia. These findings likely are due to endotoxin produced by E. coli, affecting hemodynamics, blood clotting, and cellular and humoral immunity. This approach will affect the interpretation of the CRP ratio during the recovery process. These limitations make the interpretation of the CRP ratio in our study less informative. One dog, which was euthanized because of refractory BP, had a biphasic CRP response pattern similar to that described in connection with poor prognosis in humans with CAP.

Regarding other variables, dogs with msBP were characterized by a more pronounced left shift and lymphopenia and were significantly more hypoxemic. Respiratory samples in dogs with msBP were characterized by significantly more pronounced neutrophilia, eosinopenia, and lymphopenia compared to dogs with IsBP. These variables therefore could be useful as early markers aiding in the identification of dogs with a more severe course of BP. Escherichia coli as a causative agent additionally was correlated with a more severe course of BP. Moreover, coagulation abnormalities were detected only in dogs with msBP caused by E. coli. These findings likely are due to endotoxin produced by E. coli, affecting hemodynamics, blood clotting, and cellular and humoral immunity. A similar finding of increased disease severity has been described in E. coli-induced CAP. Additionally, prolonged aPTT has been correlated with a worse prognosis in both humans and dogs with systemic inflammation or sepsis.

Initial radiographic findings were consistent with previously reported findings in dogs with BP. The resolution of the alveolar lung pattern was followed during hospitalization and follow-up visits. However, because thoracic radiographs were not repeated daily, an exact time point for the resolution could not be determined. Alveolar infiltrates resolved relatively rapidly in our study (69% of dogs had cleared alveolar infiltrates by day 10) compared to studies of humans. Only 33% of human patients with CAP had clearance of radiographic
infiltrates at day 7 and 62% at day 28, and it also has been shown that radiographic normalization lags behind clinical cure as assessed by physicians.\textsuperscript{57,58} With CAP, current research has not been able to show benefits for routinely repeating thoracic radiographs after clinical recovery.\textsuperscript{57–59} Repeating thoracic radiographs during and after hospitalization therefore is not recommended in patients with uncomplicated recovery.\textsuperscript{57} Additional information gained by thoracic radiographs, especially after the clearance of alveolar infiltrates, was minimal in our study in dogs with otherwise satisfactory clinical recovery.

Antimicrobial treatment currently is recommended for 3–6 weeks or 1–2 weeks beyond the resolution of radiographic changes.\textsuperscript{1,6,7} Markedly shorter antimicrobial courses are used in CAP. Antibiotics are recommended for 7–10 days in cases of mild-to-moderate CAP, and the use of biomarkers has proved useful in determining optimal treatment duration.\textsuperscript{27,29–31,33,34,60} No published clinical studies exist addressing the optimal duration of antimicrobials in dogs with BP, and current recommendations may overestimate the treatment duration needed, especially in uncomplicated cases. Considering the variety of infectious agents and the individual differences in the interactions between microbe and the host immune system, a need also exists in dogs with BP for customizing antibiotic treatment duration according to disease severity and response rate. In our study, normalization of CRP was used to guide duration of antimicrobial treatment in 8 of 17 dogs and resulted in significantly decreased treatment duration compared to 9 of 17 conventionally treated dogs. It would have been ideal to randomize the chosen treatment regimen and stratify the randomization according to disease severity. Instead, conventional treatment was used at the beginning of the study, because previous information on the applicability of CRP to predict treatment duration was lacking. When clinical experience was gained and serum CRP was found to reflect the recovery process well, it was considered safe to stop administering antibiotics after CRP normalization. Ending antimicrobials at the point of CRP normalization was still considered premature and, to increase safety, antimicrobials were administered for 5–7 days after CRP normalization. Relapses of BP were not noted in dogs receiving a CRP-guided course of antibiotics, and therefore, the approach appears to be safe. However, because the incidence of relapse was low in both groups, our study was not able to identify an optimal end point for antimicrobial treatment and even shorter courses than those used in the CRP-guided group may have been sufficient in dogs with BP. Additionally, the small number of dogs and lack of randomization are limitations, and larger randomized studies are warranted.

In conclusion, dogs with BP had significantly increased serum CRP, SAA, and Hp at presentation, and CRP and SAA decreased rapidly after initiation of treatment and reflected the recovery process well. When CRP normalization was used to guide the duration of antibiotic treatment, treatment duration was significantly decreased without increasing the number of relapses.

---

**Footnotes**

\textsuperscript{a} Thrombotest\textsuperscript{®}, Nycomed Pharma, Oslo, Norway
\textsuperscript{b} DG-APTT Synth Kit, Diagnostic Grifols S.A., Parets del Valles, Spain
\textsuperscript{c} LifeAssays canine CRP point-of-care system, LifeAssays AB, Lund, Sweden
\textsuperscript{d} Department of Veterinary and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
\textsuperscript{e} Advia 1800, Siemens AG, Erlangen, Germany
\textsuperscript{f} SAA-1, Eiken Chemical Company, Tokyo, Japan
\textsuperscript{g} PHASE Haptoglobin Assay Cat. No. TP-801, Tridelta Development Limited, Maynooth, County Kildare, Ireland
\textsuperscript{h} PASW Statistics 18, SPSS Inc, Chicago, IL
\textsuperscript{i} SAS\textsuperscript{®} System for Windows, version 9.3, SAS Institute Inc, Cary, NC
\textsuperscript{j} R version 3.2.3, The R Foundation for Statistical Computing, Vienna, Austria

**Acknowledgments**

The authors thank Dr Merja Rantala and technicians Lilia Jääskeläinen, Suvi Virkkala, and Merja Ranta for their contribution in laboratory analytics and Laura Parikka for technical assistance. We thank biostatistician Sofia Männikkö for her contribution to statistical analyses.

**Conflict of Interest Declaration:** S.J. Viitanen has received research grants from the Finnish Foundation of Veterinary Research and the Finnish Veterinary Foundation. These funding sources did not have any influence on the study design, sample collection, interpretation of the results, or preparation of the manuscript.

**Off-label Antimicrobial Declaration:** Intravenous and peroral cefuroxime for the treatment of pneumonia.

**References**

1. Ford RB. Bacterial pneumonia. In: Bonagura JD, ed. Kirk’s Current Veterinary Therapy XIV, 14th ed. St. Louis, MO: Saunders Elsevier; 2009:658–662.
2. Thayer G, Robinson S. Bacterial bronchopneumonia in the dog—a review of 42 cases. J Am Anim Hosp Assoc 1984;20:731–735.
3. Jameson PH, King LA, Lappin MR, Jones RL. Comparison of clinical signs, diagnostic findings, organisms isolated, and clinical outcome in dogs with bacterial pneumonia: 93 cases (1986–1991). J Am Vet Med Assoc 1995;206:206–209.
4. Radhakrishnan A, Drobatz KJ, Culp WT, King LG. Community-acquired infectious pneumonia in puppies: 65 cases (1993–2002). J Am Vet Med Assoc 2007;230:1493–1497.
5. Wingfield WE. Arterial blood gases in dogs with bacterial pneumonia. J Vet Emerg Crit Care 1997;7:75–78.
6. Dear JD. Bacterial pneumonia in dogs and cats. Vet Clin North Am Small Anim Pract 2014;44:143–159.
7. Johnson LR. Bacterial pneumonia. In: Johnson LR, ed. Clinical Canine and Feline Respiratory Medicine, 1st ed. Ames, IA: Blackwell Publishing; 2010:130–135.
8. Eckersall PD, Bell R. Acute phase proteins: Biomarkers of infection and inflammation in veterinary medicine. Vet J 2010;185:23–27.
9. Ceron JJ, Eckersall PD, Martinynez-Subielta S. Acute phase proteins in dogs and cats: Current knowledge and future perspectives. Vet Clin Pathol 2005;34:85–99.
10. Yamamoto S, Shida T, Okumura T, et al. Determination of C-reactive protein in serum and plasma from healthy dogs and dogs with pneumonia by ELISA and slide reversed passive latex agglutination test. Vet Q 1994;16:74–77.
11. Yamamoto S, Shida T, Honda M, et al. Serum C-reactive protein and immune responses in dogs inoculated with bordetella bronchiseptica (phase I cells). Vet Res Commun 1994;18:347–357.
12. Jergens AE, Schreiner CA, Frank DE, et al. A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 2003;17:291–297.
13. Tecles F, Spiranelli E, Bonfanti U, et al. Preliminary studies of serum acute-phase protein concentrations in hematologic and neoplastic diseases of the dog. J Vet Intern Med 2005;19:865–870.
14. Kjelgaard-Hansen M, Jensen AL, Houser GA, et al. Use of serum C-reactive protein as an early marker of inflammatory activity in canine type II immune-mediated polyarthritis: Case report. Acta Vet Scand 2006;48:9.
15. Darowski R, Wawron W, Kostro K. Changes in CRP, SAA and haptoglobin produced in response to ovariohysterectomy in healthy bitches and those with pyometra. Theriogenology 2007;67:321–327.
16. Lowrie M, Penderis J, Eckersall PD, et al. The role of acute phase proteins in diagnosis and management of steroid-responsive meningitis-arthritis in dogs. Vet J 2009;182:125–130.
17. Mendez JC, Carretón E, Martínez-Subiela S, et al. Acute phase protein response in heartworm-infected dogs after adulticide treatment. Vet Parasitol 2015;209:194–203.
18. Viitanen SJ, Laurila HP, Lilja-Maula LI, et al. Serum C-reactive protein as a diagnostic biomarker in dogs with bacterial respiratory diseases. J Vet Intern Med 2014;28:84–91.
19. Matijatko V, Mrljak V, Kis I, et al. Evidence of an acute phase response in dogs naturally infected with Babesia canis. Vet Parasitol 2007;144:242–250.
20. Nielsen L, Toft N, Eckersall PD, et al. Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma. J Vet Intern Med 2007;21:1231–1236.
21. Sasanelli M, Paradies P, de Caprariis D, et al. Acute-phase proteins in dogs naturally infected with Leishmania infantum during and after long-term therapy with allopurinol. Vet Res Commun 2007;31(Suppl 1):335–338.
22. Mansfield CS, James FE, Robertson ID. Development of a clinical severity index for dogs with acute pancreatitis. J Am Vet Med Assoc 2008;233:936–944.
23. Gebhardt C, Hirschberger J, Rau S, et al. Use of C-reactive protein to predict outcome in dogs with systemic inflammatory response syndrome or sepsis: Original study. J Vet Emerg Crit Care 2009;19:450–458.
24. Galezowski AM, Sned ECR, Kidney BA, Jackson ML. C-reactive protein as a prognostic indicator in dogs with acute abdomen syndrome. J Vet Diagn Invest 2010;22:395–401.
25. Mylonakis ME, Ceron JJ, Leonides L, et al. Serum acute phase proteins as clinical phase indicators and outcome predictors in naturally occurring canine monocytic ehrlichiosis. J Vet Intern Med 2011;25:811–817.
26. Jitpean S, Holst BS, Hoglund OV, et al. Serum insulin-like growth factor-I, iron, C-reactive protein, and serum amyloid A for prediction of outcome in dogs with pyometra. Theriogenology 2014;82:43–48.
27. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax 2009;64(Suppl 3):iii1–iii55.
28. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011;17(Suppl 6):E1–E59.
29. Fau ML, Fau WR, Anzueto A, Fau-Bartlett JG, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27–S72.
30. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006;174:84–93.
31. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines Vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA 2009;302:1059–1066.
32. Long W, Deng X, Zhang Y, et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011;16:819–824.
33. Ehl S, Gering B, Bartmann P, et al. C-reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics 1997;99:216–221.
34. Jasswal RS, Kaushal RK, Goel A, Pathania K. Role of C-reactive protein in deciding duration of antibiotic therapy in neonatal septicemia. Indian Pediatr 2003;40:880–883.
35. Martínez-Subiela S, Ginell PJ, Ceron JJ. Effects of different glucocorticoid treatments on serum acute phase proteins in dogs. Vet Rec 2004;154:814–817.
36. Harvey JW, West CL. Prednisone-induced increases in serum alpha-2-globulin and haptoglobin concentrations in dogs. Vet Pathol 1987;24:90–92.
37. Kuribayashi T, Shimada T, Matsumoto M, et al. Determination of serum C-reactive protein (CRP) in healthy beagle dogs of various ages and pregnant beagle dogs. Exp Anim 2003;52:387–390.
38. Nilsson TK, Boman K, Jansson JH, et al. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at -70 degrees C for 8–12 weeks and after storage at 25 degrees C for 1–12 weeks. Thromb Res 2005;116:249–254.
39. Hilstrom A, Twedten H, Lillehook I. Evaluation of an in-clinic serum amyloid A (SAA) assay and assessment of the effects of storage on SAA samples. Acta Vet Scand 2010;52:8.
40. Pasella S, Baralla A, Canu E, et al. Pre-analytical stability of the plasma proteomes based on the storage temperature. Proteome Sci 2013;11:10.
41. Ibraimi F, Ekberg B, Kriz D, et al. Preparation of a portable point-of-care in vitro diagnostic system, for quantification of canine C-reactive protein, based on a magnetic two-site immunoassay. Anal Bioanal Chem 2013;405:6001–6007.
42. Christensen M, Jacobsen S, Ichiyagami T, Kjelgaard-Hansen M. Evaluation of an automated assay based on monoclonal anti-human serum amyloid A (SAA) antibodies for measurement of canine, feline, and equine SAA. Vet J 2012;194:332–337.
43. Eckersall P, Duthie S, Safi S, et al. An automated biochemical assay for haptoglobin: Prevention of interference from albumin. Comp Haematol Int 1999;9:117–124.
44. Viitanen SJ, Lappalainen A, Rajamaki MM. Co-infections with respiratory viruses in dogs with bacterial pneumonia. J Vet Intern Med 2015;29:544–551.
45. Christensen MB, Langhorn R, Goddard A, et al. Comparison of serum amyloid A and C-reactive protein as diagnostic markers of systemic inflammation in dogs. Can Vet J 2014;55:161–168.
46. Zhydkov A, Christ-Crain M, Thomann R, et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin Chem Lab Med 2015;53:559–566.

47. Thiem U, Niklaus D, Schilhoff B, et al. C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. Age Ageing 2009;38:693–697.

48. Conner JG, Eckersall PD, Ferguson J, Douglas TA. Acute phase response in the dog following surgical trauma. Res Vet Sci 1988;45:107–110.

49. Coelho L, Povoa P, Almeida E, et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007;11:R92.

50. Moreno MS, Nietmann H, Matias CM, Lobo SM. C-reactive protein: A tool in the follow-up of nosocomial pneumonia. J Infect 2010;61:205–211.

51. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008;32:726–732.

52. Coelho LM, Salluh JI, Soares M, et al. Patterns of C-reactive protein RATIO response in severe community-acquired pneumonia: A cohort study. Crit Care 2012;16:R53.

53. Bone RC. Gram-negative sepsis: A dilemma of modern medicine. Clin Microbiol Rev 1993;6:57–68.

54. Marrie TJ. Community-acquired pneumonia due to Escherichia coli. Clin Microbiol Infect 1998;4:717–723.

55. Hemmelgarn C, Gannon K. Heatstroke: Clinical signs, diagnosis, treatment, and prognosis. Compend Contin Educ Vet 2013;35:E3.

56. Mihajlovic D, Lendak D, Mitic G, et al. Prognostic value of hemostasis-related parameters for prediction of organ dysfunction and mortality in sepsis. Turk J Med Sci 2015;45:93–98.

57. Bruns AH, Oosterheert JJ, Prokop M, et al. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007;45:983–991.

58. Bruns AH, Oosterheert JJ, El Moussaoui R, et al. Pneumonia recovery: Discrepancies in perspectives of the radiologist, physician and patient. J Gen Intern Med 2010;25:203–206.

59. Suren P, Try K, Eriksson J, et al. Radiographic follow-up of community-acquired pneumonia in children. Acta Paediatr 2008;97:46–50.

60. Schuetz P, Batscharoff M, Dusemund F, et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: A post-study survey. Eur J Clin Microbiol Infect Dis 2010;29:269–277.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Fig S1. Serum C-reactive protein (CRP), serum amyloid A (SAA) and Haptoglobin (Hp) concentrations dogs with bacterial pneumonia (BP) (n = 19) during the disease and follow up period.

Table S1. Respiratory sampling technique, information on treatment outcome, prior antimicrobial treatment, bacterial culture and antimicrobial susceptibility results as well as information on antimicrobial treatment regimen of individual dogs (n = 19) with bacterial pneumonia.